As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the ...

Sen. Elizabeth Warren urges FTC to scrutinize Novo Nordisk's $16.5 billion acquisition of Catalent over concerns of increased ...

Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) is a terrific stock for many reasons. The company continues to deliver excellent financial results thanks to a lineup of medicines with incredibly ...

(RTTNews) - Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in Washington, D.C., to answer questions regarding the ...

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...